Side-by-side · Research reference
MK-677vsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed13/45 cited
BFDA-ApprovedVerified14/45 cited
MK-677
Oral GHS · Ibutamoren
Oral capsule · 1×/day
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
MK-677
Tirzepatide
Primary target
Ghrelin receptor (GHS-R1a)Murphy 1998
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Pulsatile pattern preserved despite long half-lifeMurphy 1998
Glucose-dependent insulin release preserves physiological feedback
Origin
Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
MK-677
Tirzepatide
Standard dose
10–25 mg / day oralNass 2008
25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.
—
Frequency
Once daily, oral
—
Lower / starter dose
5 mg / day
—
Evidence basis
Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008Murphy 1998
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
8–16 weeks per cycle (off-cycle to reset receptor sensitivity)
Indefinite for chronic indication
Reconstitution
Oral, no reconstitution
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
Pre-sleep preferred for natural GH pulse alignment
Once weekly, any time of day
Half-life
~24 hrNass 2008
Once-daily dosing covers 24 hours.
~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
04Side Effects & Safety
Parameter
MK-677
Tirzepatide
Increased appetite
Strong appetite increase via ghrelin agonism
—
Water retention
Mild edema, paresthesias
—
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis)
—
Cardiovascular
No clear adverse signal in trials; congestive heart failure caution
—
Drowsiness
Common, especially during initial weeks
—
Pregnancy / OB
Avoid
Contraindicated
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
MK-677
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
- ·Congestive heart failure (caution)
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
MK-677
- ·Untreated diabetes
- ·Pre-diabetes
- ·Severe insulin resistance
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
MK-677
Tirzepatide
1. Form
Capsule or oral solution. No injection.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Site
Oral. Take with or without food.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Pre-sleep preferred — aligns with natural GH pulse.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Capsule: room temp ≤25 °C, dry place.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Caveat
Monitor HbA1c every 8–12 weeks during chronic use.
Pen-supplied. Research vial: 27–31G insulin syringe.